Waterloo Capital L.P. Has $552,000 Stock Holdings in STERIS plc $STE

Waterloo Capital L.P. increased its stake in STERIS plc (NYSE:STE) by 20.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,298 shares of the medical equipment provider’s stock after purchasing an additional 392 shares during the period. Waterloo Capital L.P.’s holdings in STERIS were worth $552,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Avantax Advisory Services Inc. grew its holdings in STERIS by 16.4% during the first quarter. Avantax Advisory Services Inc. now owns 3,631 shares of the medical equipment provider’s stock worth $823,000 after purchasing an additional 511 shares during the period. Cetera Investment Advisers increased its stake in STERIS by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 6,999 shares of the medical equipment provider’s stock worth $1,586,000 after acquiring an additional 63 shares during the period. HB Wealth Management LLC bought a new position in STERIS in the 1st quarter valued at about $556,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in STERIS by 0.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,488 shares of the medical equipment provider’s stock worth $8,950,000 after purchasing an additional 371 shares during the last quarter. Finally, LPL Financial LLC grew its position in STERIS by 7.6% in the first quarter. LPL Financial LLC now owns 38,400 shares of the medical equipment provider’s stock valued at $8,703,000 after acquiring an additional 2,696 shares during the last quarter. 94.69% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on STE shares. Morgan Stanley boosted their price target on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Finally, Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Stock Performance

NYSE STE opened at $263.27 on Tuesday. The firm has a market cap of $25.84 billion, a P/E ratio of 40.32 and a beta of 1.02. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The company’s 50 day moving average is $247.21 and its 200-day moving average is $241.92. STERIS plc has a 12-month low of $200.98 and a 12-month high of $268.30.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Activity at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the completion of the transaction, the vice president directly owned 33,669 shares of the company’s stock, valued at $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,195 shares of company stock worth $5,312,571 in the last 90 days. Company insiders own 1.07% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.